Ц.Билэгтсайхан
Loading...
Товч нэр
Ц.Билэгтсайхан
Бүтэн нэр
Цолмон Билэгтсайхан
Латин нэр
Tsolmon Bilegtsaikhan
Албан тушаал
Проректор
Эрдмийн цол
Дэд профессор
Боловсролын зэрэг
Доктор (Ph.D)
ORCID
Scopus Author ID
16 results
Now showing 1 - 10 of 16
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Additional file 1 of Pneumococcal carriage and disease in adults hospitalised with community-acquired pneumonia in Mongolia: prospective pneumonia surveillance program (2019–2022)(Figshare (United Kingdom), 2025-01-01) ;Mungun, Tuya ;Ulziibayar, Munkhchuluun ;Nguyen, Cattram D. ;Batsaikhan, PurevsurenSuuri, Bujinlkham - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Additional file 1 of Pneumococcal carriage and disease in adults hospitalised with community-acquired pneumonia in Mongolia: prospective pneumonia surveillance program (2019–2022)(Figshare (United Kingdom), 2025-01-01) ;Mungun, Tuya ;Ulziibayar, Munkhchuluun ;Nguyen, Cattram D. ;Batsaikhan, PurevsurenSuuri, Bujinlkham - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Additional file 1 of Factors associated with severe pneumonia in adults hospitalised with community-acquired pneumonia in Mongolia(Figshare (United Kingdom), 2026-01-01) ;Amy Simkiss ;Munkhchuluun Ulziibayar ;Purevsuren Batsaikhan ;Bujinlkham SuuriDashtseren LuvsantserenSupplementary Material 1: Supplementary Table 1. Describes demographic characteristics and risk factors with multiple categories in adults hospitalised with clinical community acquired pneumonia by severity status. The data in this table expands upon the binary categories used for these variables in Table 1. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Pneumococcal carriage and disease in adults hospitalised with community-acquired pneumonia in Mongolia: prospective pneumonia surveillance program (2019-2022)(2025-11) ;Mungun, Tuya ;Ulziibayar, Munkhchuluun ;Nguyen, Cattram D ;Batsaikhan, PurevsurenSuuri, BujinlkhamBACKGROUND: Streptococcus pneumoniae is an important cause of pneumonia in older adults, however, serotyping and indirect impact information from low and middle-income countries is lacking. Mongolia has a childhood 13-valent pneumococcal conjugate vaccine (PCV13) program, but no adult pneumococcal vaccination program. We describe pneumococcal carriage rates, disease and serotype distribution among adults hospitalised with pneumonia, and explore changes over the COVID-19 pandemic period. METHODS: Adults (≥ 18 years) hospitalised with clinical pneumonia were enrolled over 3 years (March 2019-February 2022) into a prospective pneumonia surveillance program. Nasopharyngeal swabs were tested to detect pneumococci using lytA qPCR and molecular serotyping by DNA microarray and metagenomics. Pneumococcal pneumonia was identified using serotype-specific urinary antigen detection and BinaxNOW® assays. Pneumococcal carriage and pneumonia prevalence were assessed over the COVID-19 period with log-binomial regression used to estimate prevalence and adjusted prevalence ratios (pre- versus early- and late-COVID-19 periods). RESULTS: Of 3,178 pneumonia cases, S. pneumoniae was identified in 12.1% (333/2,759) of swabs and 8.6% (253/2,925) of urine samples. PCV13 serotype carriage prevalence was 3.1% (82/2,663) and non-PCV13 serotype carriage prevalence 5.7% (152/2,663). In the late-COVID-19 period, pneumococcal carriage prevalence was reduced by 66% (aPR 0.34, 95%CI 0.25-0.46) and pneumococcal pneumonia by 82% (aPR 0.18, 95%CI 0.12-0.27) compared with the pre-COVID-19 transmission period. CONCLUSION: Despite paediatric vaccination with high coverage, we identified some residual PCV13 serotypes with predominance of non-PCV13 serotypes carried and causing disease in adults. Direct adult vaccination which targets these serotypes will potentially reduce disease in adults in Mongolia. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Association between quantitative computed tomography metrics and pulmonary function in patients with post-COVID-19 pulmonary fibrosis: a single-center cross-sectional study(Springer Science and Business Media LLC, 2026-08-26) ;Bayaraa, Odonchimeg; ;Galbadrakh, Ninjbadgar ;Bayarsaikhan, Dalai - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Association between prostate cancer development and TARBP1(Mongolian National University of Medical Sciences, 2025-03-31); ; ; ; Objective: Prostate cancer is the most frequent cancer among elderly men worldwide and second cause of cancer-related deaths in man. Prostate cancer characterized a clinically heterogeneous and genetic alterations in cells play a pivotal role in carcinogenesis. A detailed understandings of the genetic alterations in cancer cells are important for developing new therapeutic medicine. Transactivation response RNA-binding protein1 (TARBP1) encodes a protein with RNA-binding, tRNA methyltransferase activity, and RNA interference regulation functions, but its association with prostate cancer remains unclear. The aim of this study was to investigate clinical significance of TARBP1 in prostate cancer. Methods: Relative messenger ribonucleic acid (mRNA) and protein expression of TARBP1 in prostate cancer cell and tumor tissue was determined by qRT-PCR and Western blot analysis. LNCaP cells with lentivirus vector to silence the expression of TARBP1 were injected into nude mice. After 24 days, the mice were killed and tumor tissues were excised. The size of tumors was measured using a ruler and body weight of mice were weighed using a scale. Results: Through qRT-PCR and Western blot analysis, we validated that the expression levels of TARBP1 was decreased in TARBP1-knockdown prostate cancer cell compared with cells transfected with negative control LV-shNC RNA. The tumor growths were significant smaller in the group B (LNCaP-LV-shTARBP1) compared with group A (LNCaP-LV-shNC). Knocking down TARBP1 significantly suppressed the tumor progression of BALB/C nude xenograft. Moreover, body weight of mice in LNCaP-LV-shNC group increased significant slowly compared with LNCaP-LV-shTARBP1 group. The result of western blot analysis for TARBP1 in tumor tissues from xenograft nude mice bearing orthotopic LNCaP tumors shows that the expression of TARBP1 was also significantly decreased in the LNCaP-LV-shTARBP1 group compared with LNCaP-LV-shNC group (p < 0.05). Conclusion: We revealed that the TARBP1 highly expressed in prostate cancer and its role in promoting tumor growth. TARBP1 could serve as a potential therapeutic target for prostate cancer treatment and it is also a biomarker for tumor diagnosis and prognosis. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Additional file 1 of Factors associated with severe pneumonia in adults hospitalised with community-acquired pneumonia in Mongolia(Figshare (United Kingdom), 2026-01-01) ;Amy Simkiss ;Munkhchuluun Ulziibayar ;Purevsuren Batsaikhan ;Bujinlkham SuuriDashtseren LuvsantserenSupplementary Material 1: Supplementary Table 1. Describes demographic characteristics and risk factors with multiple categories in adults hospitalised with clinical community acquired pneumonia by severity status. The data in this table expands upon the binary categories used for these variables in Table 1. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, The Impact of GPC3 rs2267531 Polymorphism on Hepatocellular Carcinoma Susceptibility(Mongolian National University of Medical Sciences, 2025-03-31); ;Yesukhei Enkhbat ;Odonchimeg Tuvshiunsaikhan ;Yundendash DashzevegMunkhtsetseg Bat-ErdeneObjectives: To evaluate the association between the GPC3 rs2267531 polymorphism and hepatocellular carcinoma (HCC) in individuals from Mongolia. Methods: This study included 270 participants, consisting of 110 males and 160 females, with a mean age of 61.0 years (±9.5). Serum samples were collected from all participants, who were categorized into three groups: 90 patients with hepatocellular carcinoma (HCC), 90 individuals in the risk group (RG), and 90 healthy controls. The collected samples were analyzed using allele-specific polymerase chain reaction (PCR). Results: No significant differences in genotype and allele frequencies were observed between the HCC group and the risk or control groups. However, the frequency of the GPC3 C allele was significantly higher in females in the HCC group. Additionally, the protective GG genotype of GPC3 was found to have a significantly lower frequency in females in the HCC group. In contrast, HCV-positive individuals exhibited a higher frequency of the GC genotype. Conclusion: The GPC3 C allele frequency is associated with HCC in females, while the heterozygote GC genotype is linked to HCV infection in both genders. These findings suggest that the GPC3 rs2267531 polymorphism may play a role in HCC susceptibility, particularly in relation to gender and HCV status. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Түрүү булчирхайн хорт хавдрын дахих прогнозыг тодорхойлсон нь(2025-05-05) ;Wei Liu; Үндэслэл: Түрүү булчирхайн хорт хавдар нь дэлхий даяар ахимаг насны эрэгтэйчүүдийн дунд түгээмэл тохиолддог бөгөөд эмнэл зүйн хувьд оношилж, эмчлэхэд нилээн төвөгтэй хавдруудын нэг юм. Түрүү булчирхайн хорт хавдар нь олон эрсдэлт хүчин зүйлсээс шалтгаалж үүсэх бөгөөд олон генийн үйл ажиллагааны өөрчлөлт, харилцан үйлчлэлээс хамаарч үүсдэг талаар судалгаануудад тэмдэглэгдсэн байна. TARBP1 нь РНХ холбогч уураг бөгөөд зарим хавдрын үед их хэмжээгээр илэрдэг байна. Зорилго: Түрүү булчирхайн хорт хавдрын биохимийн дахилтад нөлөөтэй нуклеотидын метаболизмтой холбоотой генийг тодорхойлох. Арга, аргачлал: Түрүү булчирхайн хорт хавдрын геномын атлас (TCGA-PRAD) мэдээллийн санг ашиглан нуклеотидын метаболизмтой холбоотой генүүдийг жинлэсэн генийн хамтын илэрхийллийн сүлжээний шинжилгээ (WGCNA)-аар тодорхойлов. Генийн ялгаатай экспрессийн шинжилгээгээр ач холбогдол бүхий генүүдийг тогтоов. Ялгаатай экспресслэгдсэн зарим генийг хавдрын эдэд иммуногистохими (IHC) шинжилгээгээр баталгаажуулав. Үр дүн: Түрүү булчирхайн хорт хавдрын геномын атлас мэдээллийн сангаас 481 түрүү булчирхайн хорт хавдартай өвчтний мэдээлэл, 51 эрүүл эдийн мэдээллийн өгөгдөл судалгаанд хамрагдав. Түрүү булчирхайн хорт хавдрын эд болон эрүүл эдийн хооронд статистик ач холбогдол бүхий ялгаатай экспресслэгдсэн нуклеотидын метаболизмтой холбоотой 105 ген тодорхойлогдов (P<0.001). Түрүү булчирхайн хорт хавдрын биохимийн дахих прогнозыг тодорхойлох 5 ген (RGS11, KAT2A, MXD3, TARBP1, WFIKKN1) тодорхойлогдов. TARBP1 нь түрүү булчирхайн хорт хавдрын эдэд эрүүл эдтэй харьцуулахад их хэмжээгээр илэрч байна. Дүгнэлт: Түрүү булчирхайн хорт хавдарт нуклеотидын метаболизмтой холбоотой зарим генийн экспресс өөрчлөгдөж байгаагаас хавдрын дахих прогнозыг тодорхойлох 5 ген байна. TARBP1 нь түрүү булчирхайн хорт хавдрын эдэд их хэмжээгээр экспресслэгдэж байна. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial(Elsevier BV, 2025-11) ;Batmunkh, Tsetsegsaikhan ;Neal, Eleanor F G ;Amraa, Otgonjargal ;Mazarakis, NadiaAltangerel, BolorBACKGROUND: COVID-19 vaccine booster doses counteract waning immunity and vaccine escape by emerging variants. We evaluated long-term immunogenicity and safety of fractional and standard BNT162b2 vaccine booster doses in Mongolia. METHODS: In this randomised, controlled, non-inferiority trial, adults primed with two doses of ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac were randomised (1:1) to receive a 15 μg (fractional dose) or 30 μg (standard dose) BNT162b2 booster. Geometric mean ratios (GMR) of IgG and surrogate virus neutralising test (sVNT) levels (Wuhan-Hu-1 and Omicron BA.1) were compared over 12 months. SARS-CoV-2 infections, and adverse and serious adverse events (SAEs), were documented. CLINICALTRIALS: gov Identifier: NCT05265065. RESULTS: Of 601 participants randomised between May 27th and September 30th, 2022, 2 (0.3 %) were lost to follow-up and 19 (3.2 %) withdrew by 12 months. IgG levels declined from 28 days to six months, stabilising thereafter. At 12 months, IgG levels were lower in the fractional compared with the standard arm for ChAdOx1-S primed participants (GMR 0.78 [95 % CI 0.63-0.96], p = 0.017). At six and 12 months, the median sVNT inhibition percentages were comparable by study arm and priming strata. Documented SARS-CoV-2 infections occurred in 25 participants (fractional dose arm n = 12; standard dose arm n = 13). From 28 days, 228 undocumented infections (≥ 1.2-fold IgG increase) occurred (fractional arm n = 112; standard arm n = 116). SAEs (n = 41) were balanced between arms, with no severe vaccine-related AEs or SAEs reported. CONCLUSIONS: 15 μg and 30 μg BNT162b2 boosters demonstrated comparable immunogenicity and favourable safety. 15 μg BNT162b2 booster doses may improve vaccine acceptability due to lower reactogenicity.Scopus© Citations 3
